Fontans Operation — Cost, Top Hospitals & Success Rates | MyMedicPlus

The Fontan operation — named after French surgeon Francis Fontan who first performed it in 1968 — is a palliative staged cardiac procedure for patients born with a single functional ventricle or complex congenital heart defects in which biventricular repair is not anatomically feasible. The procedure creates a circulation in which systemic venous (deoxygenated) blood flows passively from the inferior and superior vena cavae directly into the pulmonary arteries without passing through a pumping chamber, relying entirely on venous pressure and the passive driving force of the single functional ventricle to pull blood through the lungs.

The Fontan circulation is physiologically distinct from the normal two-ventricle circulation: without a dedicated sub-pulmonary pump, pulmonary blood flow is driven by relatively low pressure (10–15 mmHg), and the single ventricle bears the combined workload of both systemic and pulmonary circulations. This creates a permanently elevated systemic venous pressure and relatively low cardiac output — a substrate for long-term complications including Fontan-associated liver disease, protein-losing enteropathy, plastic bronchitis, arrhythmias, and progressive ventricular failure.

The modern Fontan is performed in stages, typically as the final step of a three-stage palliation strategy in infancy and early childhood. The first stage (Norwood or Blalock-Taussig shunt) is performed in the neonatal period; the second stage (bidirectional Glenn or hemi-Fontan) connects the superior vena cava to the pulmonary artery at 3–6 months of age; and the Fontan completion (lateral tunnel or extracardiac conduit) connects the inferior vena cava to the pulmonary artery, typically at 2–4 years of age. The extracardiac conduit Fontan — using a synthetic tube (16–20 mm Gore-Tex) between the IVC and pulmonary artery — is the predominant technique in contemporary practice.

The Fontan operation is the definitive palliation for all single ventricle heart defects and complex congenital heart conditions where biventricular repair is not achievable. The most common diagnoses leading to Fontan include: tricuspid atresia (absence of the tricuspid valve with a hypoplastic or absent right ventricle); hypoplastic left heart syndrome (HLHS — severe underdevelopment of the left heart including hypoplastic left ventricle, aorta, and ascending aortic structures); heterotaxy syndrome (complex cardiac situs abnormalities with single functional ventricle); double-inlet left ventricle; pulmonary atresia with intact ventricular septum; and unbalanced atrioventricular septal defects.

Approximately 1 in 3,000 live births requires Fontan palliation. Advances in neonatal cardiac surgery, anaesthesia, and intensive care have transformed survival from under 10% in the 1970s to 70–90% survival to adulthood in current series at specialist centres. The focus of contemporary congenital cardiac care has shifted to optimising long-term outcomes in the growing 'Fontan population' — currently estimated at over 70,000 adults in the US alone — who face unique cardiovascular, hepatic, haematological, and quality of life challenges.

Ideal Fontan candidates have adequately sized pulmonary arteries (Nakata index above 250 mm²/m²), low pulmonary vascular resistance (below 2–3 Wood units), adequate single ventricular function (ejection fraction above 50%), no significant atrioventricular valve regurgitation, and no additional anatomical obstacles to passive pulmonary blood flow. Catheterisation data (pulmonary artery pressures, pulmonary vascular resistance, pulmonary artery sizes) are obtained before the Fontan procedure to confirm haemodynamic suitability.

Contraindications to Fontan completion include elevated pulmonary vascular resistance above 4 Wood units (which prevents passive pulmonary flow), significantly impaired ventricular function, severe atrioventricular valve regurgitation causing volume overload, and markedly hypoplastic pulmonary arteries. Some patients with elevated PVR may benefit from pulmonary vasodilator therapy (sildenafil, bosentan) to reduce PVR before Fontan candidacy is reassessed. Patients with multiple prior cardiac operations, significant arrhythmias, or hepatic disease may face increased surgical risk.

The extracardiac conduit Fontan (ECC) is the current standard technique. A polytetrafluoroethylene (PTFE/Gore-Tex) tube of 16–20 mm diameter is anastomosed from the inferior vena cava to the pulmonary artery without opening the right atrium, reducing the risk of arrhythmia compared to the older lateral tunnel technique. Most Fontans are performed with cardiopulmonary bypass; some centres perform the ECC as an off-pump procedure. A small fenestration (4 mm opening) between the conduit and the atrium is created in selected high-risk patients to provide a pop-off valve during the early post-operative period — reducing right-heart pressures at the cost of mild cyanosis.

The lateral tunnel Fontan (intraatrial tunnel) uses the native right atrial wall as part of the tunnel from the IVC to the pulmonary artery; this avoids prosthetic material but requires opening the right atrium and carries higher late arrhythmia rates than ECC. The original atriopulmonary connection (classic Fontan) is no longer performed due to very high rates of supraventricular arrhythmias and right atrial dilation. Conversion from atriopulmonary to ECC Fontan is now performed in specialist centres for patients with the old-style Fontan who develop refractory arrhythmias or deteriorating haemodynamics. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

Fontan operation transforms an otherwise fatal physiology into a survivable and often functionally active life. Modern series from specialist centres report operative mortality under 2–5%, 10-year survival of 80–90%, and 20-year survival of 70–80%. Most Fontan patients achieve New York Heart Association functional class I–II and can participate in school, moderate physical activity, and employment. Quality of life in Fontan patients, while impaired compared to healthy controls, is substantially better than with unoperated single ventricle disease, which is universally fatal in infancy without intervention.

Contemporary outcomes in high-volume congenital heart centres with experienced multidisciplinary teams (congenital cardiac surgeons, paediatric and adult congenital cardiologists, hepatologists, haematologists, and neuropsychological support) continue to improve. Exercise capacity, as measured by peak VO2 on cardiopulmonary exercise testing, averages 60–70% of predicted normal — sufficient for most activities of daily living. Pregnancy is possible for selected female Fontan patients with good ventricular function and low pulmonary pressures, managed in specialist centres with high-risk obstetric teams.

Peri-operative complications include pleural effusions — a hallmark of early Fontan physiology as high venous pressures cause third-space fluid accumulation — occurring in 30–50% of patients, sometimes requiring prolonged chest drain drainage or fenestration. Low cardiac output state, arrhythmias (junctional ectopic tachycardia, complete heart block), phrenic nerve palsy, and chylothorax are additional early complications. Long ICU stays of 1–3 weeks are common in complex cases.

Long-term Fontan-specific complications define the ongoing challenge of Fontan management: Fontan-associated liver disease (FALD) from chronic venous congestion — occurring in nearly all Fontan patients to some degree, progressing to cirrhosis and hepatocellular carcinoma risk in a significant minority; protein-losing enteropathy (PLE) in 5–10% — a life-threatening complication with 50% 5-year mortality; plastic bronchitis (bronchial cast formation) in 2–3%; supraventricular arrhythmias (atrial flutter, atrial fibrillation) in 25–50% by 20 years; and progressive single ventricular failure requiring transplantation in approximately 10–15% by 20 years. Thromboembolic events (stroke, pulmonary emboli) occur in 5–15% due to sluggish venous flow and require lifelong anticoagulation consideration.

Post-operative recovery from Fontan completion is gradual. Patients typically spend 3–7 days in the paediatric cardiac ICU, followed by 2–3 weeks on the ward. Chest drains for pleural effusions often extend the hospital stay; some patients require 4–6 weeks of hospitalisation. Activity restriction is observed for 3 months, followed by gradual return to school and age-appropriate activities. Annual cardiology follow-up with ECG, echocardiography, and periodic cardiac catheterisation is essential to monitor ventricular function, conduit integrity, and pulmonary pressures.

Adult Fontan patients require transition to specialist adult congenital heart disease (ACHD) units — a process that should begin in adolescence (age 14–16) and be complete by age 18. Annual surveillance includes echocardiogram, MRI of Fontan conduit and ventricular function, liver imaging (ultrasound and MRI for fibrosis grading), liver biopsy in select cases, cardiopulmonary exercise testing, and holter monitoring for arrhythmias. Antiplatelet therapy (aspirin) or anticoagulation (warfarin, direct oral anticoagulants) is used in most Fontan patients; the optimal regimen remains an area of active clinical research. Fontan patients planning pregnancy should be referred for pre-conception counselling at an ACHD centre.

Fontan surgery in the US is one of the most complex and expensive paediatric cardiac procedures. Total costs including all three stages of palliation (Norwood, Glenn, Fontan) typically exceed USD 300,000–600,000, with the Fontan stage alone averaging USD 100,000–200,000. Most paediatric heart surgeries in the US are covered by Medicaid (for eligible low-income families) or private health insurance. In the UK, congenital heart surgery is performed exclusively in NHS-designated specialist congenital heart centres at no direct cost to families.

For families from middle- and lower-income countries, several high-volume congenital cardiac surgery centres in India (including AIIMS, Narayana Health, and Fortis hospitals) perform Fontan operations with outcomes comparable to leading Western centres at costs of USD 8,000–20,000 — a fraction of US prices. These centres operate dedicated congenital heart programmes with experienced teams. International families seeking Fontan surgery abroad should verify the centre's annual Fontan volume, surgical mortality data, and paediatric cardiac ICU capability. Long-term follow-up arrangements must be established locally before and after the procedure.

The Fontan operation is currently the only definitive palliation for single ventricle congenital heart disease; there is no medical alternative that achieves similar survival in the long term. For patients who are not Fontan candidates due to elevated pulmonary vascular resistance, ongoing pulmonary vasodilator therapy (sildenafil, tadalafil, bosentan) may reduce PVR sufficiently to allow Fontan completion at a later date. Hybrid approaches combining catheter-based and surgical interventions extend the window of candidacy for some patients.

For patients with failing Fontan circulation, heart transplantation is the definitive rescue option and provides a two-ventricle circulation; outcomes are somewhat inferior to non-congenital heart transplantation due to prior surgical complexity and immune sensitisation, with 5-year post-transplant survival of approximately 60–70%. Mechanical circulatory support as a bridge to transplantation is increasingly used. Gene therapy and stem cell approaches to ventricular regeneration are areas of active preclinical research but are not currently clinical options.